|
As per the request submitted by fda medwatch program, this report is being resubmitted as report number 1649833-2016--70010-1.This report was initially submitted as 1649833-2015-70027 - 1, april 28, 2016.Description from original follow-up medwatch report as follows: while entering tracking database implant information, a patient was observed to have received a second implant of the same position (aortic).The surgeon's office was contacted and the operative notes were obtained, which explain why the re-do aortic valve replacement (avr) was done.The patient was diagnosed with paravalvular leak (pvl).Patient was re-operated and a new valve onxace-21 s/n (b)(4) was implanted.The valve being explanted had dehisced just right of the right coronary commisure.Lntraop transesophageal echo showed no pvl post valve replacement.Patient transferred to icu having tolerated the re-op well.The reason this is being reported is pvl is defined in the aats/sts guidelines as valve-related and reportable.It is also an expected adverse event, and is listed among the expected adverse events possible for a heart valve patient, in section 5 of the ifu.
|